The metabolic syndrome, diabetes, and Alzheimer's disease

Revista de Investigacion Clinica

Volumn 62, Issue 4, 2010, Pages 343-349

  García Lara, Juan Miguel Antonio ^a   Aguilar Navarro, Sara ^a   Gutiérrez Robledo, Luis Miguel ^b   Ávila Funes, José Alberto ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b INSTITUTO NACIONAL DE GERIATRÍA   (Mexico)

Author keywords

Alzheimer's disease; Case Control study; Cognition; Dementia; Metabolic syndrome

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DEMENTIA; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MEXICO; REGRESSION ANALYSIS; TERTIARY HEALTH CARE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CASE-CONTROL STUDIES; CHOLESTEROL, LDL; COMORBIDITY; DIABETES MELLITUS; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MEXICO; OBESITY; RISK FACTORS; URBAN POPULATION;

EID: 78549273660     PISSN: 00348376     EISSN: 00348376     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Yaari R, Corey-Bloom J. Alzheimer's disease. Semin Neurol 2007: 27; 32-41.
2. Kalaria RN, Maestre GE, Arizaga R, et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol 2008: 7; 812-26.
3. Cummings JL. Alzheimer's disease. N Engl J Med 2004; 351: 56-67.
4. Nelson NW. Differential diagnosis of Alzheimer's dementia and vascular dementia. Dis Mon 2007; 53: 148-51.
5. Breteler MM. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 2000; 21: 153-60.
6. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-28.
7. Whelan DM, Roy RC. Diseases of aging that emerge from the metabolic syndrome. Anesthesiol Clin 2006; 24: 599-619.
8. Kudo T, Imaizumi K, Tanimukai H, et al. Are cerebrovascular factors involved in Alzheimer's disease? Neurobiol Aging 2000; 21: 215-24.
9. Aguilar-Salinas CA, Rojas R, Gomez-Perez FJ, et al. High prevalence of metabolic syndrome in Mexico. Arch Med Res 2004; 35: 76-81.
10. Villalpando-Berumen JM, Mejia-Arango S, Aguilar-Salinas CA, et al. Apolipoprotein E epsilon4, Alzheimer's disease, and cognitive performance in elderly Mexican Mestizos. J Am Geriatr Soc 2008; 56: 677-82.
11. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1143-53.
12. Morris JC. Clinical assessment of Alzheimer's disease. Neurology 1997; 49: 7-10.
13. Welsh-Bohmer KA, Mohs RC. Neuropsychological assessment of Alzheimer's disease. Neurology 1997; 49: 11-3.
14. Mirra SS. Neuropathological assessment of Alzheimer's disease: the experience of the Consortium to Establish a Registry for Alzheimer's Disease. Int Psychogeriatr 1997; 9(Suppl. 1): 263-8.
15. Buckholtz N. Background and purpose of the Consortium to Establish a Registry for Alzheimer's Disease. Neurology 1997; 49(Suppl. 3): S1.
16. Aguilar-Salinas CA, Rojas R, Gomez-Perez FJ, et al. The metabolic syndrome: a concept hard to define. Arch Med Res 2005; 36: 223-31.
17. Biessels GJ, Staekenborg S, Brunner E, et al. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006; 5: 64-74.
18. Yaffe K. Metabolic syndrome and cognitive decline. Curr Alzheimer Res 2007; 4: 123-6.
19. Razay G, Vreugdenhil A, Wilcock G. The metabolic syndrome and Alzheimer disease. Arch Neurol 2007; 64: 93-6.
20. Luchsinger JA, Reitz C, Honig LS, et al. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005; 65: 545-51.
21. Vanhanen M, Koivisto K, Moilanen L, et al. Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology 2006; 67: 843-7.
22. Zhu X, Lee HG, Perry G, et al. Alzheimer disease, the two-hit hypothesis: an update. Biochim Biophys Acta 2007; 1772: 494-502.
23. Launer LJ. Demonstrating the case that AD is a vascular disease: epidemiologic evidence. Ageing Res Rev 2002; 1: 61-77.
24. van den Berg E, Biessels GJ, de Craen AJ, et al. The metabolic syndrome is associated with decelerated cognitive decline in the oldest old. Neurology 2007; 69: 979-85.
25. Craft S. Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Disord 2006; 20: 298-301.
26. Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-5.
27. Whitmer RA, Sidney S, Selby J, et al. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005; 64: 277-81.
28. Kraja AT, Rao DC, Weder AB, et al. An evaluation of the metabolic syndrome in a large multi-ethnic study: the Family Blood Pressure Program. Nutr Metab (Lond) 2005; 2: 17.
29. Seux ML, Staessen JA, Forette F. [Treatment of isolated systolic arterial hypertension and prevention of dementia in aged patients. The Syst-Eur multicenter study]. Arch Mal Coeur Vaiss 1999; 92: 1083-7.
30. Moretti R, Torre P, Antonello RM, et al. Risk factors for vascular dementia: hypotension as a key point. Vasc Health Risk Manag 2008; 4: 395-402.
31. Zhu X, Smith MA, Honda K, et al. Vascular oxidative stress in Alzheimer disease. J Neurol Sci 2007; 257: 240-6.
32. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447-51.
33. Razay G, Vreugdenhil A, Wilcock G. Obesity, abdominal obesity and Alzheimer disease. Dement Geriatr Cogn Disord 2006; 22: 173-6.
34. Chiang CJ, Yip PK, Wu SC, et al. Midlife risk factors for subtypes of dementia: a nested case-control study in Taiwan. Am J Geriatr Psychiatry 2007; 15: 762-71.
35. Mielke MM, Zandi PP, Sjogren M, et al. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 2005; 64: 1689-95.
36. Kalmijn S, Launer LJ, Ott A, et al. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol 1997; 42: 776-82.
37. West NA, Haan MN, Morgenstern H. The PPAR-gamma Pro12Ala polymorphism and risk of cognitive impairment in a longitudinal study. Neurobiol Aging 2008; 16: 2008e.
38. Canizales-Quinteros S, Aguilar-Salinas CA, Ortiz-Lopez MG, et al. Association of PPARG2 Pro12Ala variant with larger body mass index in Mestizo and Amerindian populations of Mexico. Hum Biol 2007; 79: 111-9.
39. Quin W, Haroutunian V, Katsel P, et al.PGC-1α expression decreases in the Alzheimer disease brain as a function of dementia. Arch Neurol 2009; 66: 352-61.
40. Yaffe K. Metabolic syndrome and cognitive disorders: is the sum greater than its parts? Alzheimer Dis Assoc Disord 2007; 21: 167-71.
41. Aguilar-Salinas CA, Rojas R, Gomez-Perez FJ, et al. [The metabolic syndrome: a concept in evolution]. Gac Med Mex 2004; 140(Suppl. 2): 41-8.